Citi’s Issuer Services business, acting through Citibank N.A., has been appointed by Adaptimmune Therapeutics plc (“Adaptimmune”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products, as the depositary bank for their Nasdaq listed American Depositary Receipt (ADR) programme. Adaptimmune’s ADR programme trades on the Nasdaq Global Select Market under the symbol “ADAP”.

“Citi is delighted to be appointed by Adaptimmune as depositary bank for its Nasdaq listed ADR programme”, said Dirk Jones, Global Head of Issuer Services, at Citi. “We are confident that we will be able to assist Adaptimmune in expanding their investor outreach through the support of our Investor Relations Advisory team and our unparalleled equity distribution network.”

For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.

NOTES TO EDITORS

About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the company aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous cells by using engineered, increased affinity T cell receptor (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune’s lead program is an affinity enhanced therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialisation of the NY-ESO TCR program. The company currently has over 100 employees. For more information: http://www.adaptimmune.com

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://new.citi.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

Citi MediaCapucine Boncenne+44 (0) 20 7508 9355capucine.boncenne@citi.comorAdaptimmuneWill RobertsVice President, Investor RelationsT: (215) 966-6264E: will.roberts@adaptimmune.comorMargaret HenryHead of PRT: +44 (0)1235 430036Mob: +44 (0)7710 304249E: margaret.henry@adaptimmune.com

Citigroup (NYSE:C)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Citigroup Charts.
Citigroup (NYSE:C)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Citigroup Charts.